

Brian M Zeglis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6746076/publications.pdf>

Version: 2024-02-01

71
papers

3,992
citations

109321

35
h-index

118850

62
g-index

73
all docs

73
docs citations

73
times ranked

3881
citing authors

#	ARTICLE	IF	CITATIONS
1	PET imaging with ⁸⁹ Zr: From radiochemistry to the clinic. <i>Nuclear Medicine and Biology</i> , 2013, 40, 3-14.	0.6	338
2	A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1389-1396.	5.0	247
3	Click Chemistry and Radiochemistry: The First 10 Years. <i>Bioconjugate Chemistry</i> , 2016, 27, 2791-2807.	3.6	197
4	A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. <i>Dalton Transactions</i> , 2011, 40, 6168.	3.3	169
5	Role of Metalation in the Topoisomerase II \pm Inhibition and Antiproliferation Activity of a Series of β -Heterocyclic-N ⁴ -Substituted Thiosemicarbazones and Their Cu(II) Complexes. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2391-2398.	6.4	168
6	Pretargeted Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1553-1559.	5.0	143
7	Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels-Alder Click Chemistry. <i>Bioconjugate Chemistry</i> , 2011, 22, 2048-2059.	3.6	142
8	¹⁸ F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. <i>Bioconjugate Chemistry</i> , 2016, 27, 298-301.	3.6	127
9	First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹ Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 900-906.	5.0	126
10	Enzyme-Mediated Methodology for the Site-Specific Radiolabeling of Antibodies Based on Catalyst-Free Click Chemistry. <i>Bioconjugate Chemistry</i> , 2013, 24, 1057-1067.	3.6	123
11	Site-Specifically Labeled Immunoconjugates for Molecular Imaging-Part 1: Cysteine Residues and Glycans. <i>Molecular Imaging and Biology</i> , 2016, 18, 1-17.	2.6	101
12	Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. <i>Cancer Research</i> , 2017, 77, 3931-3941.	0.9	91
13	Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics. <i>Molecular Pharmaceutics</i> , 2015, 12, 3575-3587.	4.6	88
14	Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15850-15855.	7.1	85
15	Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses. <i>Journal of Nuclear Medicine</i> , 2016, 57, 453-459.	5.0	80
16	Establishment of the <i>In Vivo</i> Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 124-133.	4.1	79
17	Underscoring the Influence of Inorganic Chemistry on Nuclear Imaging with Radiometals. <i>Inorganic Chemistry</i> , 2014, 53, 1880-1899.	4.0	75
18	Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. <i>Cancer Research</i> , 2018, 78, 1820-1832.	0.9	69

#	ARTICLE	IF	CITATIONS
19	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. <i>Clinical Cancer Research</i> , 2020, 26, 2871-2881.	7.0	69
20	Harnessing ⁶⁴ Cu/ ⁶⁷ Cu for a theranostic approach to pretargeted radioimmunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28316-28327.	7.1	67
21	Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging. <i>Bioconjugate Chemistry</i> , 2014, 25, 2123-2128.	3.6	64
22	Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. <i>Bioconjugate Chemistry</i> , 2016, 27, 1789-1795.	3.6	60
23	Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 2: Peptide Tags and Unnatural Amino Acids. <i>Molecular Imaging and Biology</i> , 2016, 18, 153-165.	2.6	60
24	The Bioconjugation and Radiosynthesis of ⁸⁹ Zr-DFO-labeled Antibodies. <i>Journal of Visualized Experiments</i> , 2015, , .	0.3	60
25	Pretargeting of internalizing trastuzumab and cetuximab with a ¹⁸ F-tetrazine tracer in xenograft models. <i>EJNMMI Research</i> , 2017, 7, 95.	2.5	58
26	Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 170.	3.5	57
27	Leveraging Bioorthogonal Click Chemistry to Improve ²²⁵ Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 868-880.	7.0	55
28	The inverse electron demand Diels–Alder click reaction in radiochemistry. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 285-290.	1.0	53
29	A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. <i>Theranostics</i> , 2016, 6, 2267-2277.	10.0	53
30	Exploring Structural Parameters for Pretargeting Radioligand Optimization. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8201-8217.	6.4	52
31	PARP-Targeted Radiotherapy in Mouse Models of Glioblastoma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1225-1233.	5.0	51
32	On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion. <i>Nuclear Medicine and Biology</i> , 2021, 93, 19-21.	0.6	43
33	A Bone-Seeking <i>trans</i> -Cyclooctene for Pretargeting and Bioorthogonal Chemistry: A Proof of Concept Study Using ^{99m} Tc- and ¹⁷⁷ Lu-Labeled Tetrazines. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9381-9389.	6.4	41
34	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹ Zr-Pertuzumab PET/CT. <i>Radiology</i> , 2020, 296, 370-378.	7.3	40
35	Site-Specifically Labeled Antibody–Drug Conjugate for Simultaneous Therapy and ImmunoPET. <i>Molecular Pharmaceutics</i> , 2018, 15, 892-898.	4.6	38
36	The Impact of Fc ¹³ RI Binding on Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1174-1182.	5.0	37

#	ARTICLE	IF	CITATIONS
37	Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma. <i>Molecular Pharmaceutics</i> , 2018, 15, 1729-1734.	4.6	36
38	The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of ²²⁵ Ac-labelled radioimmunoconjugates. <i>Chemical Communications</i> , 2018, 54, 2599-2602.	4.1	33
39	Dual Radionuclide Theranostic Pretargeting. <i>Molecular Pharmaceutics</i> , 2019, 16, 4416-4421.	4.6	33
40	Preclinical ⁸⁹ Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 771-776.	5.0	31
41	The Influence of Glycans-Specific Bioconjugation on the Fc γ RI Binding and <i>In vivo</i> Performance of ⁸⁹ Zr-DFO-Pertuzumab. <i>Theranostics</i> , 2020, 10, 1746-1757.	10.0	31
42	Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability. <i>Bioconjugate Chemistry</i> , 2018, 29, 1364-1372.	3.6	29
43	Dendrimer Scaffold for the Amplification of In Vivo Pretargeting Ligations. <i>Bioconjugate Chemistry</i> , 2018, 29, 2734-2740.	3.6	28
44	Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 672-692.	1.0	26
45	A brief overview of metal complexes as nuclear imaging agents. <i>Dalton Transactions</i> , 2019, 48, 14547-14565.	3.3	26
46	A comparative evaluation of the chelators H 4 octapa and CHX-A ϵ -DTPA with the therapeutic radiometal ⁹⁰ Y. <i>Nuclear Medicine and Biology</i> , 2016, 43, 566-576.	0.6	25
47	Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. <i>ChemistryOpen</i> , 2014, 3, 48-53.	1.9	24
48	A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma. <i>Small</i> , 2021, 17, e2007705.	10.0	24
49	Harnessing PET to track micro- and nanoplastics in vivo. <i>Scientific Reports</i> , 2021, 11, 11463.	3.3	24
50	Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept. <i>Theranostics</i> , 2019, 9, 6706-6718.	10.0	23
51	Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy. <i>Molecular Pharmaceutics</i> , 2019, 16, 2259-2263.	4.6	19
52	Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy. <i>Nature Protocols</i> , 2021, 16, 3348-3381.	12.0	19
53	The synthesis and evaluation of N1-(4-(2-[¹⁸ F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([¹⁸ F]-FESAHA), A PET radiotracer designed for the delineation of histone deacetylase expression in cancer. <i>Nuclear Medicine and Biology</i> , 2011, 38, 683-696.	0.6	18
54	Molecular Imaging of Ovarian Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 827-833.	5.0	17

#	ARTICLE	IF	CITATIONS
55	DiPODS: A Reagent for Site-Specific Bioconjugation via the Irreversible Rebridging of Disulfide Linkages. <i>Bioconjugate Chemistry</i> , 2020, 31, 2789-2806.	3.6	14
56	ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody. <i>Clinical Cancer Research</i> , 2022, 28, 948-959.	7.0	11
57	A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2020, 17, 3140-3147.	4.6	10
58	Manipulating the In Vivo Behaviour of ⁶⁸ Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1496.	4.1	10
59	Pretargeted PET of Osteodestructive Lesions in Dogs. <i>Molecular Pharmaceutics</i> , 2022, 19, 3153-3162.	4.6	10
60	Synthesis and evaluation of ¹⁸ F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 769-781.	5.5	9
61	The Impact of Tyrosine Iodination on the Aggregation and Cleavage Kinetics of MMP-9-Responsive Peptide Sequences. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 579-587.	5.2	8
62	Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	7
63	Synthesis and Comparative <i>In Vivo</i> Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. <i>Bioconjugate Chemistry</i> , 2021, 32, 1255-1262.	3.6	7
64	Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging. <i>Journal of Visualized Experiments</i> , 2015, , e52335.	0.3	6
65	⁸⁹ Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe. <i>Molecules</i> , 2020, 25, 2315.	3.8	6
66	Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. <i>Molecular Pharmaceutics</i> , 2021, 18, 338-346.	4.6	6
67	Near-Infrared Intraoperative Chemiluminescence Imaging. <i>ChemMedChem</i> , 2016, 11, 1978-1982.	3.2	5
68	Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	5
69	Removal of Fc Glycans from [⁸⁹ Zr]-DFO-Anti-CD8 Prevents Peripheral Depletion of CD8 ⁺ T Cells. <i>Molecular Pharmaceutics</i> , 2020, 17, 2099-2108.	4.6	5
70	A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	0
71	ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape. <i>Molecular Imaging and Biology</i> , 2017, 19, 325-327.	2.6	0